多鲁曲韦在非洲儿童中的群体药代动力学：CHAPAS-4 试验的结果。

IF 2.5 4区医学 Q3 INFECTIOUS DISEASES

Journal of the Pediatric Infectious Diseases Society Pub Date : 2024-09-26 DOI:10.1093/jpids/piae076

Hylke Waalewijn, Roeland E Wasmann, Alasdair Bamford, Diana M Gibb, Helen M McIlleron, Angela Colbers, David M Burger, Paolo Denti

{"title":"多鲁曲韦在非洲儿童中的群体药代动力学：CHAPAS-4 试验的结果。","authors":"Hylke Waalewijn, Roeland E Wasmann, Alasdair Bamford, Diana M Gibb, Helen M McIlleron, Angela Colbers, David M Burger, Paolo Denti","doi":"10.1093/jpids/piae076","DOIUrl":null,"url":null,"abstract":"We characterized population pharmacokinetics in 42 African children receiving once-daily 25 mg (14 to <20 kg) or 50 mg (>20 kg) dolutegravir. Coadministration with emtricitabine and tenofovir alafenamide reduced dolutegravir bioavailability by 19.6% (95% confidence interval: 8.13%-30.8%) compared with zidovudine or abacavir with lamivudine. Nevertheless, concentrations remained above efficacy targets, confirming current dosing recommendations.","PeriodicalId":17374,"journal":{"name":"Journal of the Pediatric Infectious Diseases Society","volume":" ","pages":"496-500"},"PeriodicalIF":2.5000,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424990/pdf/","citationCount":"0","resultStr":"{\"title\":\"Population Pharmacokinetics of Dolutegravir in African Children: Results From the CHAPAS-4 Trial.\",\"authors\":\"Hylke Waalewijn, Roeland E Wasmann, Alasdair Bamford, Diana M Gibb, Helen M McIlleron, Angela Colbers, David M Burger, Paolo Denti\",\"doi\":\"10.1093/jpids/piae076\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We characterized population pharmacokinetics in 42 African children receiving once-daily 25 mg (14 to <20 kg) or 50 mg (>20 kg) dolutegravir. Coadministration with emtricitabine and tenofovir alafenamide reduced dolutegravir bioavailability by 19.6% (95% confidence interval: 8.13%-30.8%) compared with zidovudine or abacavir with lamivudine. Nevertheless, concentrations remained above efficacy targets, confirming current dosing recommendations.\",\"PeriodicalId\":17374,\"journal\":{\"name\":\"Journal of the Pediatric Infectious Diseases Society\",\"volume\":\" \",\"pages\":\"496-500\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424990/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the Pediatric Infectious Diseases Society\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/jpids/piae076\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Pediatric Infectious Diseases Society","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jpids/piae076","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

我们研究了 42 名非洲儿童每日一次服用 25 毫克（14-20 千克）多卢特拉韦的群体药代动力学特征。与齐多夫定或阿巴卡韦与拉米夫定合用相比，与恩曲他滨和替诺福韦-阿拉非酰胺合用可使多鲁特韦酯的生物利用度降低19.6%（95%CI：8.13-30.8%）。尽管如此，其浓度仍高于疗效目标值，这也证实了目前的用药建议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Population Pharmacokinetics of Dolutegravir in African Children: Results From the CHAPAS-4 Trial.

We characterized population pharmacokinetics in 42 African children receiving once-daily 25 mg (14 to <20 kg) or 50 mg (>20 kg) dolutegravir. Coadministration with emtricitabine and tenofovir alafenamide reduced dolutegravir bioavailability by 19.6% (95% confidence interval: 8.13%-30.8%) compared with zidovudine or abacavir with lamivudine. Nevertheless, concentrations remained above efficacy targets, confirming current dosing recommendations.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of the Pediatric Infectious Diseases Society Medicine-Pediatrics, Perinatology and Child Health

CiteScore

6.70

自引率

0.00%

发文量

179

期刊介绍： The Journal of the Pediatric Infectious Diseases Society (JPIDS), the official journal of the Pediatric Infectious Diseases Society, is dedicated to perinatal, childhood, and adolescent infectious diseases. The journal is a high-quality source of original research articles, clinical trial reports, guidelines, and topical reviews, with particular attention to the interests and needs of the global pediatric infectious diseases communities.